Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Growth and Income
The company is expected to grow its earnings per share 39.1% in 2010, 22.2% in 2011, and 17.5% over the long term. Its trailing 12-month return on equity is 23.3%. The stock also offers investors a dividend yield of 1.3%.
This Zacks #1 Rank stock trades at 19x 2010 consensus EPS estimates and 15x 2011 consensus EPS estimates.
Business
Lennox International designs, manufactures, and markets a range of products for heating, ventilation, air conditioning, and refrigeration markets in the United States, Canada, and internationally.
Recent News
On July 27, Lennox had second-quarter revenue of $872 million, up 11% from the year-ago quarter. The company had EPS of $0.97, topping the Zacks Consensus by 13 cents, or 15.5%. In the last three quarters, Lennox has beaten the Zacks Consensus Estimate by 179%
CEO Todd Bluedorn said, "All business segments realized strong revenue and profit growth in the second quarter on solid operational execution and improved end market conditions from a year ago."
Guidance
Looking ahead, the company is encouraged by the improved end market conditions, but Lennox remains mindful of global economic uncertainties and higher commodities prices. For the full year, management raised its revenue growth guidance to 5%-8% and adjusted EPS growth of 24%-38% over last year.
Estimates
In the last month, the Zacks Consensus Estimate for 2010 has increased 15 cents, or 6.5%, to $2.46. The Zacks Consensus Estimate for 2011 has climbed 13 cents, or 4.5%, to $3.01.
The Chart
Lennox shares peaked in late April around $51. Its stock sold off with the overall market, and it has been in trading range since May. The low end of the range is $41-$42, while the high end of the range is $46. A break above the $46 level would be bullish and should take the stock back up to its highs of the year. A break below the 200-day, which has provided support for the last three months, would be negative.
Read the full reports :
Snapshot Report on LII